Table 1 Overlapping meta-analyses of GATA3 and ERα at cutoff of 4 studies (19%)
Overlap of ERα and GATA3 (4 or more studies) | |||
|---|---|---|---|
ERα = 257, GATA3 = 194, OVERLAP = 108 | |||
ERα | GATA3 | ||
GATA3 | 48% | 100% | GATA binding protein 3 |
ESR1 | 100% | 67% | estrogen receptor 1 (estrogen receptor alpha) |
XBP1 | 38% | 52% | X-box binding protein 1 |
FOXA1 | 33% | 52% | forkhead box A1 |
FOXC1 | 19% | 24% | forkhead box C1 |
TFF1 | 33% | 52% | trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) [pS2] |
TFF3 | 38% | 67% | trefoil factor 3 (intestinal) |
NRIP1 | 19% | 19% | nuclear receptor interacting protein 1 (RIP140) |
BCL2 | 43% | 67% | B-cell CLL/lymphoma 2 |
ACADSB | 38% | 48% | acyl-Coenzyme A dehydrogenase, short/branched chain |
LAF4 | 43% | 38% | lymphoid nuclear protein related to AF4 |
COX6C | 38% | 33% | cytochrome c oxidase subunit VIc |
FBP1 | 38% | 33% | fructose-1,6-bisphosphatase 1 |
IGF1R | 38% | 33% | insulin-like growth factor 1 receptor |
IRS1 | 33% | 33% | insulin receptor substrate 1 |
CELSR2 | 38% | 38% | cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila) |
LRBA | 38% | 38% | LPS-responsive vesicle trafficking, beach and anchor containing |
NAT1 | 33% | 57% | N-acetyltransferase 1 (arylamine N-acetyltransferase) |
SCNN1A | 38% | 57% | sodium channel, nonvoltage-gated 1 alpha |
DNAJC12 | 33% | 48% | DnaJ (Hsp40) homolog, subfamily C, member 12 |
RAB31 | 38% | 19% | RAB31, member RAS oncogene family |
RABEP1 | 33% | 43% | rabaptin, RAB GTPase binding effector protein 1 |
SELENBP1 | 33% | 33% | selenium binding protein 1 |
FAAH | 38% | 33% | fatty acid amide hydrolase |
TNFSF10 | 38% | 33% | tumor necrosis factor (ligand) superfamily, member 10 |
SLC22A18 | 33% | 24% | solute carrier family 22 (organic cation transporter), member 1 |
SLC39A6 | 38% | 57% | solute carrier family 39 (zinc transporter), member 6 (Estrogen regulated protein LIV-1) |
SLC40A1 | 33% | 19% | solute carrier family 40 (iron-regulated transporter), member 1 |
SLC9A3R1 | 19% | 43% | solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 1 |
SIAH2 | 33% | 33% | seven in absentia homolog 2 (Drosophila) |
SERPINA3 | 38% | 24% | serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 |
SERPINA5 | 33% | 19% | serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 5 |
SERPINA6 | 19% | 24% | serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 6 |
ERBB3 | 33% | 19% | v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) |
ERBB4 | 19% | 48% | v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
IL6ST | 24% | 38% | interleukin 6 signal transducer (gp130, oncostatin M receptor) |
KIAA0040 | 24% | 24% | KIAA0040 protein |
KIAA0303 | 33% | 43% | Similar to Mouse serine/threonine protein kinase MAST205 |
KIAA0882 | 19% | 19% | KIAA0882 protein |
ITPR1 | 24% | 33% | inositol 1,4,5-triphosphate receptor, type 1 |
INPP4B | 24% | 43% | inositol polyphosphate-4-phosphatase, type II, 105kDa |
JMJD2B | 24% | 48% | jumonji domain containing 2B |
C10orf116 | 24% | 52% | chromosome 10 open reading frame 116 |
ANXA9 | 19% | 43% | annexin A9 |
AR | 19% | 33% | androgen receptor (dihydrotestosterone receptor; Kennedy disease) |
CCND1 | 19% | 48% | cyclin D1 (PRAD1: parathyroid adenomatosis 1) |
CCNG2 | 19% | 24% | cyclin G2 |
CA12 | 19% | 38% | carbonic anhydrase XII |
CACNA1D | 19% | 33% | calcium channel, voltage-dependent, L type, alpha 1D subunit |
CACNA2D2 | 19% | 43% | calcium channel, voltage-dependent, alpha 2/delta subunit 2 |
DNALI1 | 24% | 43% | dynein, axonemal, light intermediate polypeptide 1 |
AGR2 | 19% | 33% | anterior gradient 2 homolog (Xenepus laevis) |
GFRA1 | 33% | 48% | GDNF family receptor alpha 1 |
HPN | 19% | 43% | hepsin (transmembrane protease, serine 1) |
GREB1 | 19% | 38% | GREB1 protein |
MAPT | 19% | 38% | microtubule-associated protein tau |
MLPH | 24% | 33% | melanophilin |
KRT18 | 24% | 33% | keratin 18 |
PTPRT | 24% | 48% | protein tyrosine phosphatase, receptor type, T |
STC2 | 24% | 33% | stanniocalcin 2 |
SCUBE2 | 33% | 24% | CEGP1 protein |
PTGER3 | 33% | 24% | prostaglandin E receptor 3 (subtype EP3) |
PDCD4 | 33% | 24% | programmed cell death 4 (neoplastic transformation inhibitor) |
MUC1 | 33% | 29% | mucin 1, transmembrane |
NPY1R | 33% | 29% | neuropeptide Y receptor Y1 |
FLJ20366 | 38% | 24% | hypothetical protein FLJ20366 |
TLE3 | 33% | 29% | transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila) |
13CDNA73 | 24% | 29% | hypothetical protein CG003 |
AGTR1 | 24% | 29% | Angiotensin II receptor, type 1 |
ASAH1 | 24% | 29% | N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
BF | 24% | 24% | B-factor, properdin |
ENPP1 | 24% | 29% | ectonucleotide pyrophosphatase/phosphodiesterase 1 |
QDPR | 24% | 29% | quinoid dihydropteridine reductase |
C9orf116 | 19% | 29% | chromosome 9 open reading frame 116 |
CYFIP2 | 19% | 29% | cytoplasmic FMR1 interacting protein 2 |
GRIA2 | 19% | 29% | glutamate receptor, ionotropic, AMPA 2 |
GSTM3 | 19% | 29% | Glutathione S-transferase M3 (brain) |
ACOX2 | 19% | 29% | acyl-Coenzyme A oxidase 2, branched chain |
LRIG1 | 19% | 29% | leucine-rich repeats and immunoglobulin-like domains 1 |
PLAT | 19% | 29% | plasminogen activator, tissue |
MAGED2 | 19% | 29% | Melanoma antigen family D, 2 |
THRAP2 | 19% | 29% | thyroid hormone receptor associated protein 2 |
MSX2 | 24% | 24% | msh homeo box homolog 2 (Drosophila) |
UGCG | 24% | 24% | UDP-glucose ceramide glucosyltransferase |
ALCAM | 19% | 24% | activated leukocyte cell adhesion molecule |
ALDH4A1 | 19% | 24% | aldehyde dehydrogenase 4 family, member A1 |
ABCA3 | 24% | 19% | ATP-binding cassette, sub-family A (ABC1), member 3 |
LOC51760 | 19% | 24% | B/K protein |
PRSS23 | 19% | 24% | protease, serine, 23 |
RHOH | 24% | 19% | ras homolog gene family, member H |
TFAP2B | 19% | 24% | transcription factor AP-2 beta (activating enhancer binding protein 2 beta) |
WFDC2 | 24% | 19% | WAP four-disulfide core domain 2 |
ANGPTL1 | 19% | 19% | angiopoietin-like 1 |
BCAS1 | 19% | 19% | breast carcinoma amplified sequence 1 |
CYP2B6 | 19% | 19% | cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6 |
EML2 | 19% | 19% | echinoderm microtubule associated protein like 2 |
FLNB | 19% | 19% | filamin B, beta (actin binding protein 278) |
GPR160 | 19% | 19% | G protein-coupled receptor 160 |
LU | 19% | 19% | Lutheran blood group (Auberger b antigen included) |
MRPS30 | 19% | 19% | mitochondrial ribosomal protein S30 |
PTE2B | 19% | 19% | peroxisomal acyl-CoA thioesterase 2B |
RERG | 19% | 19% | RAS-like, estrogen-regulated, growth inhibitor |
RNASE4 | 19% | 19% | ribonuclease, RNase A family, 4 |
RNF110 | 19% | 19% | polycomb group ring finger 2 (MEL-18) |
SEMA3C | 19% | 19% | sema domain, immunoglobulin domain (Ig), short basic domain, (semaphorin) 3C |
SULT2B1 | 19% | 19% | sulfotransferase family, cytosolic, 2B, member 1 |
TPBG | 19% | 19% | trophoblast glycoprotein |
TPD52 | 19% | 19% | tumor protein D52 |
KAL1 | 19% | 19% | Kallmann syndrome 1 sequence |